secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0000950170-22-003356
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics reports FY2021 net loss $35.5M, IND cleared for DT-216 Phase 1 trial
--------------------------------------------------------------------------------

- Net loss $35.5M for FY2021 ($11.1M in Q4); cash and investments $384.1M at Dec 31, 2021.
- IND for DT-216 (Friedreich Ataxia) cleared by FDA; Phase 1 trial to begin shortly.
- Appointed Dr. Jae Kim as Chief Medical Officer to lead clinical development.
- Preclinical data on GeneTAC molecules for Fuchs endothelial corneal dystrophy to be presented at ARVO May 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017022003356/0000950170-22-003356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017022003356/dsgn-20220310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer